Trial Profile
A Randomized, Single-blind, Single-dose, 3-arm, Parallel Group Study to Determine the Pharmacokinetic Similarity of ABP 710 and Infliximab (Remicade 'Registered Trademark') in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Inflammation; Rheumatic disorders
- Focus Pharmacokinetics
- Sponsors Amgen
- 01 Nov 2017 Primary endpoint has been met. (The primary objective of this study is to determine the PK similarity (as assessed principally by AUCinf) of ABP 710 following a 5 mg/kg intravenous (IV) infusion relative to that of a 5 mg/kg IV infusion ofinfliximab (US) or a 5 mg/kg IV infusion of infliximab (EU)) as per results presented at the 25th United European Gastroenterology Week
- 01 Nov 2017 Results presented at the 25th United European Gastroenterology Week
- 17 Jun 2017 Results comparing pharmacokinetics of ABP-710 and infliximab sourced from the European Union (n=98), presented at the 18th Annual Congress of the European League Against Rheumatism